Literature DB >> 3620713

Biological differences among MCF-7 human breast cancer cell lines from different laboratories.

C K Osborne, K Hobbs, J M Trent.   

Abstract

MCF-7 human breast cancer cells are used widely for studies of tumor biology and hormone mechanism of action. Conflicting results have often been obtained in studies reported from different laboratories. In this report several biological properties were studied in four MCF-7 cell lines obtained from different laboratories. MCF-7 (ATCC), MCF-7, MCF-7 (KO), and MCF-7 (S) demonstrated similar morphology in monolayer culture. Chromosome analysis revealed that three of the lines shared several structural chromosome alterations and marker chromosomes; however, MCF-7 (ATCC) was distinctly different with virtually no chromosomal alterations shared in common with the other lines. All four lines contained variable amounts of estrogen receptor (ER) and progesterone receptor (PgR). The growth rate of MCF-7 (ATCC) was 50% slower than that of the other lines, and, unlike the other three lines, cell proliferation was unaffected by estrogen or antiestrogen treatment despite the presence of receptors. Cloning efficiency of the four lines varied over a 10-fold range. Tumorigenicity in athymic nude mice also varied considerably among these lines. MCF-7 (ATCC) grew well in ovariectomized nude mice, while the other lines required estrogen supplementation. MCF-7 (S) and MCF-7 grew rapidly with estrogen supplementation; MCF-7 (KO) grew very slowly. Antiestrogen therapy inhibited growth of MCF-7, MCF-7 (S), and MCF-7 (KO) tumors, but it had no effect on MCF-7 (ATCC). These data demonstrate that MCF-7 lines from different laboratories may have unique biological properties, despite having a similar karyotype (MCF-7, MCF-7 (S), MCF-7 (KO]. The fundamental differences in karyotype and biological properties of the MCF-7 (ATCC), and the previously reported differences in DNA restriction fragment polymorphism analyses, demonstrate that this line is derived from an entirely different patient. Investigators should carefully document the source and identity of MCF-7 cells used in published experiments.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3620713     DOI: 10.1007/bf01807363

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  24 in total

1.  Nuclear thyroid hormone receptors in a human breast cancer cell line.

Authors:  R E Burke; W L McGuire
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  In vitro model systems for the study of hormone-dependent human breast cancer.

Authors:  M E Lippman; C K Osborne; R Knazek; N Young
Journal:  N Engl J Med       Date:  1977-01-20       Impact factor: 91.245

3.  Receptor binding and processing of epidermal growth factor by human breast cancer cells.

Authors:  C K Osborene; B Hamilton; M Nover
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

4.  Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture.

Authors:  R W Furlanetto; J N DiCarlo
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

5.  Cytogenetic studies of human breast cancer lines: MCF-7 and derived variant sublines.

Authors:  J Whang-Peng; E C Lee; C S Kao-Shan; K Seibert; M Lippman
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

6.  Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.

Authors:  C K Osborne; D H Boldt; P Estrada
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration.

Authors:  P Briand; A E Lykkesfeldt
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

8.  Effect of prolactin on growth and the estrogen receptor level of human breast cancer cells (MCF-7).

Authors:  S Shafie; S C Brooks
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

9.  The role of estrogens on the proliferation of human breast tumor cells (MCF-7).

Authors:  A M Soto; C Sonnenschein
Journal:  J Steroid Biochem       Date:  1985-07       Impact factor: 4.292

10.  Estrogen and the growth of breast cancer: new evidence suggests indirect action.

Authors:  S M Shafie
Journal:  Science       Date:  1980-08-08       Impact factor: 47.728

View more
  63 in total

1.  LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines.

Authors:  Erik W Thompson; Mark Waltham; Susan J Ramus; Anne-Marie Hutchins; Jane E Armes; Ian G Campbell; Elizabeth D Williams; Phillip R Thompson; James M Rae; Michael D Johnson; Robert Clarke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

2.  Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.

Authors:  Olga Chemnitzer; Katharina Götzel; Luisa Maurer; Arne Dietrich; Uwe Eichfeld; Orestis Lyros; Boris Jansen-Winkeln; Albrecht Hoffmeister; Ines Gockel; René Thieme
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

3.  Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells.

Authors:  T Okamoto; Y Tanaka; M Kan; A Sakamoto; K Takada; J D Sato
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-02       Impact factor: 2.416

4.  Modulation of human breast cancer cell adhesion by estrogens and antiestrogens.

Authors:  R Millon; F Nicora; D Muller; M Eber; C Klein-Soyer; J Abecassis
Journal:  Clin Exp Metastasis       Date:  1989 Jul-Aug       Impact factor: 5.150

5.  Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.

Authors:  Daniel R Budman; Anthony Calabro; Lisa Rosen; Martin Lesser
Journal:  Anticancer Drugs       Date:  2012-03       Impact factor: 2.248

6.  Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.

Authors:  K Nesaretnam; R Stephen; R Dils; P Darbre
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

7.  Patient derived cell culture and isolation of CD133⁺ putative cancer stem cells from melanoma.

Authors:  Yvonne Welte; Cathrin Davies; Reinhold Schäfer; Christian R A Regenbrecht
Journal:  J Vis Exp       Date:  2013-03-13       Impact factor: 1.355

8.  Activation of estrogen-responsive genes does not require their nuclear co-localization.

Authors:  Silvia Kocanova; Elizabeth A Kerr; Sehrish Rafique; Shelagh Boyle; Elad Katz; Stephanie Caze-Subra; Wendy A Bickmore; Kerstin Bystricky
Journal:  PLoS Genet       Date:  2010-04-22       Impact factor: 5.917

9.  Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Authors:  Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow
Journal:  Mol Cancer       Date:  2010-11-18       Impact factor: 27.401

10.  The effects of TGF-alpha and 17 beta-estradiol on polyphosphoinositide metabolism in MCF-7 breast cancer cells.

Authors:  R N Etindi; A Manni; J Martel
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.